The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors
Open accessAbstract
Genetically engineered, neuroattenuated herpes simplex viruses (HSVs) expressing various cytokines can improve survival when used in the treatment of experimental brain tumors. These attenuated viruses have both copies of γ 1 34.5 deleted. Recently, we demonstrated increased survival of C57BL/6 mice bearing syngeneic GL-261 gliomas when treated with an engineered HSV expressing IL-4, as compared with treatment with the parent construct (γ 1 34.5−) alone or with a virus expressing IL-10. Herein, we report construction of a conditionally replication-competent mutant expressing both subunits of mIL-12 (M002) and its evaluation in a syngeneic neuroblastoma murine model. IL-12 induces a helper T cell subset type 1 response, which may induce more durable antitumor effects.In vitro studies showed that, when infected with M002, both Vero cells and murine Neuro-2a neuroblastoma cells produced physiologically relevant levels of IL-12 heterodimers, as determined by ELISA. M002 was cytotoxic for Neuro-2a cells and human glioma cell lines U251MG and D54MG. Neurotoxicity studies, as defined by plaque-forming units/LD 50, performed in HSV-1-sensitive A/J strain mice found that M002 was not toxic even at high doses. When evaluated in an intracranial syngeneic neuroblastoma murine model, median survival of M002-treated animals was significantly longer than the median survival of animals treated with R3659, the parent γ 1 34.5−mutant lacking any cytokine gene insert. Immunohistochemical analysis of M002-treated tumors identified a pronounced influx of CD4+T cells and macrophages as well as CD8+cells when compared with an analysis of R3659-treated tumors. We conclude that M002 produced a survival benefit via oncolytic effects combined with immunologic effects meditated by helper T cells of subset type 1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
Self-citationAttenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 822
Chou, J., Kern, E. R., Whitley, R. J., & Roizman, B. (1990) · Science · doi:10.1126/science.2173860 · Cited by 711
Self-citationCloning and expression of murine IL-12
Schoenhaut, D. S., Chua, A. O., Wolitzky, A. G., Quinn, P. M., Dwyer, C. M., McComas, W., Familletti, P. C., Gately, M. K., & Gubler, U. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.11.3433 · Cited by 470
Post, L. E., & Roizman, B. (1981) · Cell · doi:10.1016/0092-8674(81)90247-6 · Cited by 336
Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., & Lotze, M. T. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.12.6466 · Cited by 271
Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma.
Caruso, M., Pham-Nguyen, K., Kwong, Y. L., Xu, B., Kosai, K. I., Finegold, M., Woo, S. L., & Chen, S. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11302 · Cited by 227
Chambers, R., Gillespie, G. Y., Soroceanu, L., Andreansky, S., Chatterjee, S., Chou, J., Roizman, B., & Whitley, R. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1411 · Cited by 192
Self-citationBramson, J. L., Hitt, M., Addison, C. L., Muller, W. J., Gauldie, J., & Graham, F. L. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.16-1995 · Cited by 188
Markert, J. M., Malick, A., Coen, D. M., & Martuza, R. L. (1993) · Neurosurgery · doi:10.1097/00006123-199304000-00016 · Cited by 187
Self-citationKramm, C. M., Chase, M., Herrlinger, U., Jacobs, A., Pechan, P. A., Rainov, N. G., Sena-Esteves, M., Aghi, M., Barnett, F. H., Chiocca, E. A., et al. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.17-2057 · Cited by 167
Toda, M., Martuza, R. L., Kojima, H., & Rabkin, S. D. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4457 · Cited by 161
Andreansky, S. S., Soroceanu, L., Er, F., Chou, J., Markert, J. M., Gillespie, G. Y., Roizman, B., & Whitley, R. J. (1997) · PubMed · Cited by 148
Self-citationZitvogel, L., Tahara, H., Cai, Q., Storkus, W. J., Müller, G., Wolf, S. F., Gately, M. K., Robbins, P. D., & Lotze, M. T. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.12-1493 · Cited by 131
Rakhmilevich, A. L., Janssen, K., Turner, J. G., Culp, J., & Yang, N.-S. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.11-1303 · Cited by 116
Bramson, J. L., Hitt, M., Gallichan, W. S., Rosenthal, K. L., Gauldie, J., & Graham, F. L. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.3-333 · Cited by 109
Okada, H., Giezeman‐Smits, K. M., Tahara, H., Attanucci, J., Fellows, W. K., Lotze, M. T., Chambers, W. H., & Bozik, M. E. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300798 · Cited by 89
Genetically engineered HSV in the treatment of glioma: a review
Markert, J. M., Gillespie, G. Y., Weichselbaum, R. R., Roizman, B., & Whitley, R. J. (2000) · Reviews in Medical Virology · Cited by 84
Self-citationInterleukin-12 Inhibits Angiogenesis Induced by Human Tumor Cell Lines In Vivo
Majewski, S. T., Marczak, M., Szmurło, A., Jabłońska, S., & Bollag, W. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12340161 · Cited by 68
Lagunoff, M., & Roizman, B. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3615-3623.1995 · Cited by 64
Tahara, H., Lotze, M. T., Robbins, P. D., Storkus, W. J., & Zitvogel, L. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.12-1607 · Cited by 64
Jenkins, F. J., & Roizman, B. (1986) · Journal of Virology · doi:10.1128/jvi.59.2.494-499.1986 · Cited by 62
Marshall, E. (1995) · Science · doi:10.1126/science.268.5217.1555 · Cited by 57
Interleukin 12: Newest Member of the Antiangiogenesis Club
Kerbel, R. S., & Hawley, R. G. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.8.557 · Cited by 38
Systemic interleukin 12 displays anti-tumour activity in the mouse central nervous system
Kishima, H., Shimizu, K., Miyao, Y., Mabuchi, E., Tamura, K., Tamura, M., Sasaki, M., & Hakakawa, T. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.513 · Cited by 24
Macklis, J., & Madison, R. (1991) · Journal of Neuroscience · doi:10.1523/jneurosci.11-07-02055.1991 · Cited by 21
Meko, J. B., Tsung, K., & Norton, J. A. (1996) · Surgery · doi:10.1016/s0039-6060(96)80298-4 · Cited by 18
Cited by
Liu, B. L., Robinson, M., Han, Z.-Q., Branston, R. H., English, C., Reay, P., McGrath, Y., Thomas, S. K., Thornton, M., Bullock, P., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301885 · Cited by 803
Self-citationWhitley, R. J., & Roizman, B. (2002) · Wiley Encyclopedia of Molecular Medicine · doi:10.1002/0471203076.emm0597 · Cited by 700
Self-citationAn overview of current delivery systems in cancer gene therapy
El-Aneed, A. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.09.013 · Cited by 693
Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., Guest, P. J., Harrington, K. J., James, N. D., Love, C. A., McNeish, I., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 569
Self-citationNew insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
Metadata
- Authors
- Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., & Markert, J. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-02-18
- Volume
- 97
- Issue
- 5
- Pages
- 2208-2213
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2098738104
- Cited by
- 332
- References
- 27
- FWCI
- 9.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.